Salute e Benessere
TROP2-Targeted Antibody-Drug Conjugates Set to Transform NSCLC Treatment Market by 2040 | DelveInsight
Discover which indication is expected to grab the major TROP2 ADCs in NSCLC market share @
TROP2 is overexpressed in a significant proportion of NSCLC cases, including up to 64% of adenocarcinomas and 75% of squamous cell carcinomas. This widespread expression makes TROP2 an attractive target for ADCs, allowing for precise delivery of cytotoxic agents directly to tumor cells while minimizing damage to healthy tissues.
ADCs allow for the specific delivery of potent cytotoxic agents directly to tumor cells, increasing tumor cell kill and reducing off-target effects compared to conventional chemotherapy. TROP2 is highly expressed in a majority of NSCLC cases, making it a broadly applicable target. DATROWAY represents a major advancement in TROP2 ADCs, offering a promising alternative to chemotherapy for lung cancer.
Advances in antibody engineering, linker technology, and payload selection offer opportunities to increase therapeutic index, minimize toxicity, and overcome resistance observed with current regimens.
With only one therapy approved, there is an opportunity for the competitive landscape of TROP2 ADCs to treat NSCLC. Currently, the pipeline is minimal, including products such as (Gilead Sciences), (Merck and Kelun-Biotech), (Dualitybio/BioNTech), (OBI Pharma), and others.
Non-small cell lung cancer continues to pose a significant global health challenge, but the therapeutic landscape is rapidly advancing with the development of antibody–drug conjugates. These targeted therapies are engineered to deliver potent cytotoxic agents directly to tumor cells, offering new treatment opportunities for patients with specific biomarkers. Among these, TROP2 has emerged as a key therapeutic target across multiple cancer types.
TROP2-directed therapies are particularly promising, showing strong efficacy and favorable safety profiles in several major cancers. By delivering cytotoxic drugs specifically to tumor sites, they have the potential to minimize the side effects commonly associated with conventional treatments.
To date, only one TROP2 ADC, , has been approved for NSCLC. In June 2025 , Daiichi Sankyo and AstraZeneca received approval for its use in adult patients with locally advanced or metastatic EGFR-mutated NSCLC who had previously undergone EGFR-targeted therapy and platinum-based chemotherapy.
The broader adoption of TROP2 ADCs in NSCLC remains uncertain. While AstraZeneca and Daiichi Sankyo had initially withdrawn their wider marketing application for DATROWAY in NSCLC, its approval for EGFR-mutated cases represents a first-in-class achievement and an essential milestone in the field.
Learn more about the TROP2 ADCs in NSCLC @
Some of the TROP2 ADCs in NSCLC in clinical trials include (Gilead Sciences), (Merck and Kelun-Biotech), (Dualitybio/BioNTech), (OBI Pharma), and others.
is a first-in-class antibody-drug conjugate (ADC) targeting TROP2. It features a proprietary hydrolyzable linker that connects to SN-38, a topoisomerase I inhibitor, enabling potent activity against TROP2-expressing cells and their surrounding microenvironment. TRODELVY is also under investigation for potential use in metastatic non-small cell lung cancer (NSCLC).
Currently, TRODELVY is being studied in the Phase III EVOKE-03 trial in combination with KEYTRUDA for patients with metastatic NSCLC and a PD-L1 Tumor Proportion Score (TPS) ≥50%. In January 2022 , Gilead Sciences entered two clinical trial collaboration and supply agreements with Merck to assess the combination of TRODELVY and Merck's anti-PD-1 therapy, KEYTRUDA, in first-line metastatic NSCLC.
, developed by Kelun-Biotech and licensed to Merck outside Greater China , is another investigational TROP2-targeting ADC comprising a monoclonal antibody, a topoisomerase I inhibitor payload, and a novel hydrolyzable linker. As of June 30, 2024 , Merck is conducting ten global Phase III trials and Phase II basket studies evaluating sacituzumab tirumotecan alone or in combination for multiple solid tumors, including NSCLC.
In June 2025 , Merck presented data at ASCO showing that sacituzumab tirumotecan significantly improved response rates and overall survival compared with docetaxel in previously treated patients with locally advanced or metastatic EGFR mutant nonsquamous NSCLC. Additionally, in December 2024 , the US FDA granted Breakthrough Therapy Designation (BTD) for sacituzumab tirumotecan in patients with advanced or metastatic nonsquamous NSCLC harboring EGFR mutations, whose disease progressed after tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy.
is a novel TROP2-targeting ADC co-developed by DualityBio and BioNTech, designed to deliver cytotoxic agents specifically to TROP2-overexpressing cancer cells across various solid tumors. DB-1305/BNT325 is currently being evaluated in Phase II trials, including patients with NSCLC.
The anticipated launch of these emerging therapies are poised to transform the TROP2 ADCs in NSCLC market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the TROP2 ADCs in NSCLC market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about TROP2 ADCs in NSCLC clinical trials, visit @
TROP2 is highly expressed in various lung cancers. It is associated with patient prognosis, positioning TROP2-targeted ADCs as a potentially practical approach to enhance outcomes and lower toxicity relative to conventional treatments, although research is still ongoing. Advancing TROP2 ADCs for lung cancer involves enhancing linker stability, reducing off-target effects, addressing resistance mechanisms, and optimizing dosing schedules and combination therapies to maximize therapeutic benefit while controlling adverse effects.
The TROP2 ADCs in NSCLC market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2020–2040 across the leading markets, including the US, EU4 ( Germany , France , Italy , and Spain ), the UK, and Japan . The TROP2 ADCs in NSCLC target patient pool is segmented into:
Discover more about TROP2 ADCs in NSCLC in development @
The NSCLC market size has undergone a revolutionary transformation over the last decade, driven by an increase in incident cases, the continuous adoption of approved therapies primarily immune checkpoint inhibitors, the anticipated introduction of premium-priced treatments, and growing awareness of mutations such as KRAS, BRAF, c-Met, and others. NSCLC is increasingly becoming a biomarker-driven market. EGFR is one of the profitable biomarker segments, with blockbuster therapies such as TAGRISSO. TAGRISSO is now the dominant EGFR inhibitor, selling nearly annually. The non-small cell lung cancer market size is estimated to be in the leading markets (the US, EU4, the UK, and Japan ) in 2024. It is anticipated to grow with a significant CAGR during the study period (2020-2034). Leading NSCLC companies include and among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-small cell lung cancer companies, including among others.
report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key TROP-2 inhibitor companies, including among others.
report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key ADC companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/trop2-targeted-antibody-drug-conjugates-set-to-transform-nsclc-treatment-market-by-2040--delveinsight-302552562.html